Thu, June 24, 2021
Wed, June 23, 2021
Tue, June 22, 2021
Mon, June 21, 2021

Robyn Karnauskas Maintained (BTAI) at Strong Buy with Decreased Target to $125 on, Jun 23rd, 2021

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-decreased-target-to-125-on-jun-23rd-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
  • 🞛 This publication is a summary or evaluation of another publication
  • 🞛 This publication contains potentially derogatory content such as foul language or violent themes
Robyn Karnauskas of Truist Securities, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $128 to $125 on, Jun 23rd, 2021.

Robyn has made no other calls on BTAI in the last 4 months.



There are 3 other peers that have a rating on BTAI. Out of the 3 peers that are also analyzing BTAI, 0 agree with Robyn's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Robyn


  • Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $176 on, Tuesday, June 1st, 2021
  • Anita Dushyanth of "Berenberg" Initiated at Strong Buy and Held Target at $75 on, Friday, April 9th, 2021
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $95 on, Thursday, April 1st, 2021